openPR Logo
Press release

Global Transthyretin Amyloidosis Treatment Market – Insights with Market Players Alnylam Pharmaceuticals, Pfizer., Prothena Corporation, GlaxoSmithKline, Ionis Pharmaceuticals

05-02-2019 04:07 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Transthyretin Amyloidosis Treatment

Transthyretin Amyloidosis Treatment

Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart.

Transthyretin amyloidosis is a result of transthyretin produced by the liver and forms dimers, followed by monomers. Monomers aggregate to form amyloid fibrils, which are deposited in organs such as heart, nervous system, gastrointestinal tract, and kidneys. FAP is a subtype of hereditary transthyretin amyloidosis and the most common type of FAP is caused by the Val30Met variant of Transthyretin (TTR). In familial amyloid polyneuropathy, the symptoms are first detected after the patient crosses 30 years of age, however, it can also be detected as early as 20 years or as late as 80 years of age. Symptoms are divided depending on the location such as peripheral neuropathy and autonomic neuropathy. Symptoms may worsen in case excess amyloid protein starts to collect in the nerves.

Introduction of novel therapy for the treatment of transthyretin amyloidosis is expected to significantly drive the market growth

Key players in the market are focused on approval and launch of novel therapies for treatment of transthyretin amyloidosis. This in turn is expected to propel growth of the global transthyretin amyloidosis treatment market over the forecast period.

Request For Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/687

For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In July 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received marketing authorization approval for its drug TEGSEDI (inotersen) from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Key players in the market are focused on strategic partnerships in order to enhance their market share. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. partnered with Orsini Healthcare, a specialty pharmacy as distributor of ONPATTRO (patisiran) lipid complex injection.

However, high costs of recently launched drugs is expected to hinder growth of the market. For instance, according to Alnylam Pharmaceutical, Inc., the cost of Patisiran is around US$ 450,000, annually before insurance. Another drug, Inotersen manufactured by Ionis Pharmaceuticals in partnership with Akcea Therapeutics, received approval for hereditary Transthyretin Amyloidosis Polyneuropathy indication and the drug costs US$ 450,000, annually. High cost of drugs may result in lower adoption even in developed economies such as the U.S., thereby restraining growth of the market.

Key players operating in the global transthyretin amyloidosis treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Major players in the market have novel drugs in the pipeline, which are in late-stage clinical trials and are expected to receive approval in the near future. For instance, Eidos Therapeutics, Inc. is developing AG10— an orally-administered, small molecule designed to potently and selectively stabilize tetrameric TTR, thereby interfering with events that give rise to ATTR. The drug is currently in Phase 2 clinical trial. Akcea Therapeutics Inc. is co-developing AKCEA-TTR- LRx with Ionis Pharmaceuticals to inhibit the production of transthyretin. Akcea Therapeutics Inc. is focused on developing AKCEA-TTR-LRx for patients with both hereditary and wild type form of the disease. AKCEA-TTR-LRx is planning to enter clinical development in 2018

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/687

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Transthyretin Amyloidosis Treatment Market – Insights with Market Players Alnylam Pharmaceuticals, Pfizer., Prothena Corporation, GlaxoSmithKline, Ionis Pharmaceuticals here

News-ID: 1725574 • Views:

More Releases from Coherent Market Insights

Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clasado Biosciences, VW-Ingredients, Shandong Longli Biotechnology Co., Ltd, Prenexus Health., Ingredion, Tata Chemicals Ltd., Yakult Honsha Co., Ltd., Tate & Lyle, Roquette Frèr
Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clas …
Coherent Market Insights Published Most recent Prebiotics for Dietary Supplements Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business,
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., K
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca P …
Coherent Market Insights Published Most recent DNA Repair Drugs Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business, this
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, Manufacturing Process, Business Plan | Alpek S.A.B de C.V., RTP Company, BASF SE
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, M …
This comprehensive Report of the Polyethylene Terephthalate (PET) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requirement | BASF SE, Occidental Chemical Corporation
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requi …
This comprehensive Report of the Chlorine Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the market size

All 5 Releases


More Releases for TTR

SWATCH TTR TOUR CHAMPION CROWNED IN DAYS
Vermont, USA - March 16th, 2009: The time has come to crown the men’s Swatch TTR Tour Champion at the prestigious 6Star Burton US Open. After a highly charged season, Shaun White (USA) and Peetu Piiroinen (FIN) have emerged as the two Title contenders, but only one will walk away victorious after Sunday’s Slopestyle Final. However, the Halfpipe finals on Saturday will already play an important and
Kevin Pearce new Swatch TTR World Tour Champion
Stratton, VT, USA - March 21st, 2008: After a full-out season of close calls and flawless victories, US snowboarder Kevin Pearce charged through the opposition, defeating his challengers and rising to the occasion to become the new 07/08 Men’s Swatch TTR World Snowboard Tour Champion. Kevin Pearce, a Vermont native, was crowned at 04.30 pm U.S. EST at the base of Stratton Mountain in front of a mass of spectators
TTR FOUR(4)STAR BUDWEISER BUDRIDERS’ RIVERJUMP
Livigno, Italy. TTR FOUR(4)STAR event, the 2nd Edition Budweiser Budriders’ Riverjump, set the scene for Yale Cousino (USA) to display his Slopestyle skills blowing the field away to win the contest title and 700 TTR Ranking Points at Livigno, Italy, 8th -10th March, 2007. Set in one of Europe’s best Slopestyle parks, built with top Italian craftsmanship, the Mottolino Livigno snowpark consisted of one car to slide/to bonk, two rails
TTR FOUR(4)STAR BILLABONG WORLD JUNIOR PRO
Leysin, Switzerland. Unexpected stormy winds finally forced organizers of TTR FOUR(4)STAR 4th annual Billabong World Junior Pro to cancel the Slopestyle Finals at the Mont de Chaux Snowpark, Leysin, 6th-11th March, 2007, and take the semi-final results to announce the Franck April (CAN) and Marie Hucal (USA) the Billabong World Junior Champions. Bad weather affected Saturday’s original schedule so Billabong World Junior Pro organizers and riders postponed the Finals to a
INTRODUCING HOT NEW TTR FEATURES: MYSPACE, MEDIA FRIENDS, BRAND PARTNER & TTR TO …
Innsbruck, Austria. On the quest to progress, Ticket To Ride (TTR) World Snowboard Tour launches brand spanking new features on the official website www.ttrworldtour.com, including TTR Brand Partner Ranking & Media ‘Friends’ sections and TTR’s very own myspace community. Sure to shake the industry is a team manager’s dream – the Men & Women TTR Brand Partner Top 5. Composed of official Platinum and Gold TTR Brand Partners, the ranking is
TTR FIVE(5)STAR OAKLEY ARCTIC CHALLENGE
SENSATIONAL NEWS FROM TTR FIVE(5)STAR OAKLEY ARCTIC CHALLENGE AS TERJE HAAKONSEN BREAKS WORLD RECORD FOR HIGHEST AIR & KEVIN PEARCE WINS TITLE TO BECOME THE NEW TTR TOUR LEADER Oslo, Norway. The TTR FIVE(5)STAR Oakley Arctic Challenge 2007 goes down as one of the most important chapters in snowboarding history as Terje Haakonsen (NOR) sets a new World Record for the Highest Air at an incredible 9.8-metres – whilst Kevin Pearce